Newsletter Signup | Join Community | Cancer Types
Inrebic represents a new treatment option for Jakafi-resistant Myelofibrosis and significantly reduces spleen volumes.
Clinical trials are ongoing evaluating Pacritinib in MF - no significant updates were released at ASH 2019.
In addition to improving long term survival Jakafi® improves MF caused fatigue, spleenomegaly and kidney function.
Connect with others and learn about lymphoma, leukemia, hodgkin's disease and myeloproliferative neoplasms.
Jakafi associated anemia and low platelet counts can be improved with addition of thalidomide, stanozolol and prednisone
New study initiated to evaluate AVID in Myelofibrosis is underway.
Single agent Jakafi improves treatment of Myelofibrosis - researchers report on novel Jakafi combinations with Hydrea...
Leading cancer centers create combined social community with MPNRF PV Reporter & Cancer Connect to support MPN patients
AML drug Daurismo evaluated in MF - further study warranted.
Thalidomide - Jakafi Combination may be Effective for Treatment of Myelofibrosis Associated Low Blood Counts
Researchers evaluate combining Interferon and Jakafi as primary treatment for Myelofibrosis
Resources for second opinions and where to get them for PV, ET and MF
Stay current with MPN treatment advances and connect with others.
Essential Thrombocythemia, treatment and advances
Understanding Myeloproliferative Neoplasms: Polycythemia vere, essential thrombocythemia, and myelofibrosis.
Spleenomegaly from Myelofibrosis Improved with Jakafi
The PV Tracker helps patients effectively monitor their symptoms and manager their condition.
Myeloproliferative Neoplasm itching explained by David Wallace of the PV Reporter
If you have been diagnosed with myelofibrosis or polycythemia vera, you may have experienced itching as a side effect
Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life.
Looking for individuals to participate in research studies.
Research Suggests JAK Inhibitors May Cause Aggressive Lymphoma
Incyte Announces Initiation of Clinical Trial Evaluating Jakafi® for the Treatment of Essential Thrombocythemia.
All Symptomatic Polycythemia Vera Patients May Benefit From Treatment with a JAK2 Inhibitor.
International Marrow Donor Registries Reach 25 Million Potential Donors, Give Hope to Searching Blood Cancer Patients
Jakafi: First Drug Approved for Treatment of Polycythemia Vera
Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Info
Jak2, CALR, Gene Mutation Identified in Myeloproliferative Neoplasms
Health behaviors & medical history may affect the likelihood of developing polycythemia vera & essential thrombocythemia
Is it worth going to someone who specializes in the treatment of MPNs like PV MF or ET?
MF - ELZONRISTM (tagraxofusp; SL-401) trials in MF look promising: https://ir.stemline…
Read the news update about the risk of lymphoma with treatment; has anyone's doctor discussed…